Brown Shipley & Co’s AbbVie ABBV Stock Holding History

Brown Shipley & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-395	Closed	-$63K	–	123
2023 Q1	$63K	Buy	+395	New	+$60.4K	0.04%	65

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brown Shipley & Co's ABBV Position: Q2 2023 in Review

Brown Shipley & Co sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 395 shares — an estimated $63K sold.

Brown Shipley & Co first reported a position in ABBV in Q1 2023 and held it in 1 quarter. The position peaked at $63K in Q1 2023. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

Brown Shipley & Co reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
Brown Shipley & Co sold 395 AbbVie shares in Q2 2023, an estimated $63K.
Brown Shipley & Co first reported a position in AbbVie in Q1 2023 and held it in 1 quarter.
Brown Shipley & Co's AbbVie position peaked at $63K in Q1 2023.
3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Brown Shipley & Co's 13F filing for Q2 2023, filed 14 Aug 2023.